⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

Inclusion Criteria:

1. Patients with selected solid malignancies (NSCLC, SCLC, SqCCHN, melanoma, merkel cell tumor, renal, bladder, hepatocellular, triple negative breast, or gastroesophageal cancer) or Hodgkin's lymphoma
2. At least 1 measurable lesion documented on CT/MRI (RECIST criteria 1.1)
3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Appendix B: ECOG Scoring)
4. Age ≥ 18 years
5. Ability to understand the purposes and risks of the trial and has signed a IRB-approved informed consent form
6. Willingness and ability to comply with all protocol required procedures
7. For men and women of child-bearing potential, use of effective contraceptive methods during the study

Exclusion Criteria:

Patients meeting any of the following criteria will not be eligible for study entry:

1. Known infection with human immunodeficiency virus (HIV)
2. Serious nonmalignant disease or conditions that in the opinion of the investigator and/or ImaginAb could compromise protocol objectives
3. Patients who have had splenectomy.
4. Patients who have any splenic disorders that in the opinion of the investigator and/or ImaginAb could compromise protocol objectives.
5. Patients who are currently receiving any other investigational agent
6. Pregnant women or nursing mothers
7. Hepatic laboratory values:

   1. Bilirubin \> 1.5 x ULN (institutional upper limits of normal)
   2. Albumin \< 2 g/dL
   3. Other local safety laboratory test results (clinical chemistry and hematology) are determined to be exclusionary by the Investigator.
8. Known sensitivity to glutamic acid or glutamate.